Literature DB >> 22358942

Synthetic immunomodulators.

C De Simone1, G Santini, E Rosati, S Moretti.   

Abstract

CONCLUSIONS: An effective boosting of the host immunocompetence is possible through synthetic immunomodulators, keeping in mind that they are no panacea for all microbial diseases. No drug is effective on all phases or effector cells of the immune response and it is postulated that in a near future combined therapies will be attempted with antibiotics or anti-cancer agents.

Entities:  

Year:  1991        PMID： 22358942     DOI： 10.1007/BF00736796

Source DB:  PubMed          Journal:  Cytotechnology        ISSN： 0920-9069            Impact factor:   2.058


  5 in total

1.  Inosine pranobex and zidovudine metabolism.

Authors:  C De Simone; S Tzantzoglou; V Vullo; S Catania; V Trinchieri
Journal:  Lancet       Date:  1989-10-21       Impact factor: 79.321

2.  Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study.

Authors:  C De Simone; F Albertini; M Almaviva; G Angarano; F Chiodo; P Costigliola; S Delia; A Ferlini; F Gritti; G Mazzarello
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group.

Authors:  C Pedersen; E Sandström; C S Petersen; G Norkrans; J Gerstoft; A Karlsson; K C Christensen; C Håkansson; P O Pehrson; J O Nielsen
Journal:  N Engl J Med       Date:  1990-06-21       Impact factor: 91.245

Review 4.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

5.  Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.

Authors:  J A Laurie; C G Moertel; T R Fleming; H S Wieand; J E Leigh; J Rubin; G W McCormack; J B Gerstner; J E Krook; J Malliard
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.